



Impact of VLUs

VLUs are the most common type of lower extremity wound, afflicting approximately 1% of the western population during their lifetime. VLUs also represent a significant burden for patients and healthcare systems.²



26-69% of healed VLUs reoccur within the first 12 months of closure.⁶

Therapy goals for VLUs

Venous leg ulcer management includes a combination of best practice skin and wound care principles with a therapeutic goal of reducing chronic edema and promoting wound healing: 1,3,4

- Periwound skin protection
- Identification and management of wound infection and suspected biofilm
- Exudate management
- Compression therapy



28% of patients experience >10 VLU episodes in their lifetime.⁷

Compression therapy: The gold standard for VLU management

Compression therapy has been shown to increase the rate of healing compared to no compression.² Research indicates that a bandage or multi-layer compression system that is capable of creating an inelastic sleeve provides stiffness that effectively supports venous pump mechanisms.^{8,9}

Additional hemodynamics effects of compression therapy include: 10,11,12,13

- Reduced venous ambulatory hypertension and venous pooling
- Improved venous and lymphatic return
- · Reduced chronic edema and inflammation
- · Reduced leg pain

Compression therapy

3M[™] Coban[™] 2 Two-Layer Compression System

The Coban™ 2 Two-Layer Compression System provides effective compression therapy, which has been shown to contribute to effective VLU management through edema reduction, decreased pain, and improvement in a patient's daily activities.¹⁴,¹⁵ Coban™ 2 compression system is easy to apply and remove and is designed to stay in place,¹⁴,¹⁶ increasing patient compliance and the potential for more effective treatment.¹⁴,¹⊓



3M[™] Coban[™] 2 Two-Layer Compression System



3M[™] Coban[™] 2 Lite Two-Layer Compression System




VLU healing rate^{19,+}

In two large, well-controlled, retrospective analyses comparing Coban™ 2 compression system to two other compression systems, Coban™ 2 compression system demonstrated increased healing rates with a reduction in patient management costs.¹8,¹9,+


Quality of life

A retrospective analysis of 675 patient records who had a newly-diagnosed venous leg ulcers compared Coban™ 2 compression system to two other compression systems. Treatment with Coban™ 2 compression system demonstrated better health related quality of life. 19,+



(p=0.006)

- +Refer to Instructions for Use
- ¹⁹Once compression has been initiated



Protect skin

Skin damage such as maceration, erythema and weeping are often associated with VLUs. Research supports routine protection of periwound skin from excess exudate, mechanical trauma, and protection of at-risk, compromised skin as essential parts of wound management and wound bed preparation.²⁰



3M[™] Cavilon[™] No Sting Barrier Film

A gentle, effective and CHG-compatible solution for routine skin protection.



3M[™] Cavilon[™] Advanced Skin Protectant


Creates a highly durable, ultra-thin barrier that attaches to wet, weepy skin²¹ and lasts up to seven days²² – providing long lasting skin protection.

Prepare wound bed

Wound healing starts with addressing underlying issues such as bioburden and inflammation. Biofilm, present in greater than 70% of chronic wounds, causes persistent inflammation and poor wound healing.^{23,24} Effective wound management strategies may include the use of topical advanced wound care products to help address the underlying issues of biofilm, bioburden and inflammation.

3M™ Kerracontact™ Ag Dressing

Kerracontact Ag dressing uses Ag Oxysalts[™] Technology, which is designed with three missing-electrons (Ag3+), while silver contained in other silver dressings is missing only one electron (Ag1+). Kerracontact Ag dressing is a sterile, single use wound dressing effective against a variety of gram-negative and grampositive bacteria for up to seven days.²⁵ It can be used on dry wounds (when pre-moistened) or in the presence of exudate whereby it allows for transfer of fluids into a secondary dressing.






3M[™] Promogran Prisma[™] Wound Balancing Matrix

Promogran Prisma Matrix is comprised of a sterile, freeze-dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC. In the presence of exudate, it transforms into a soft, conformable, biodegradable gel, thus allowing contact with all areas of the wound. The dressing maintains an optimal healing environment that is conducive to granulation tissue formation, epithelialization and rapid wound healing.


Significantly higher percentage of wounds healed

A 12-week randomized controlled trial involving VLU patients (n = 30) showed wounds dressed with Promogran Prisma Matrix healed at 12 weeks (p = 0.04).²⁶



Optimize wound environment

Selecting products that help optimize the wound environment is important to healing. Things to consider include: maintaining an optimal environment through exudate management, providing protection from outside contaminates, and enabling easy application and removal.





Exudate management solutions



3M™ Kerramax Care™ Super-Absorbent Dressing

- Unique horizontal wicking layer draws up serous and viscous exudate, distributing it
 horizontally and vertically across the dressing, utilizing the full absorption capacity and
 preventing bulking.^{27,28}
- Super-absorbent core locks in exudate, bacteria and MMPs^{29,30,31} to reduce the risk of maceration³² and infection transfer risk³⁰ even under compression.^{31,32}
- Soft, non-woven material on both sides of the dressing allows either side to be placed on the wound and is comfortable for the patient,³¹ helping support patient compliance.



3M™ Tegaderm™ Silicone Foam Dressings

- Offers a significantly longer wear time than the leading competitive silicone foam dressings^{33,34} while being gentle to the skin.
- Unique multi-layer design absorbs and evaporates moisture away from the skin, helping reduce the potential for skin maceration and helping to promote an optimal healing environment.
- The unique patented delivery system enables easy application, even in challenging locations.



3M™ Tegaderm™ High Performance Foam Dressings

- Integrates innovative layer technology to absorb and evaporate moisture to help maintain an
 optimal wound healing environment.
- High absorbency and breathability helps reduce the risk of maceration.

Optimize wound environment

Negative pressure wound therapy

Negative pressure wound therapy (NPWT) is a method that applies sub-atmospheric pressure through a foam dressing to create an environment that promotes wound healing by drawing wound edges together, removing exudate and infectious material whereas 3M[™] V.A.C.[®] Therapy additionally reduces edema.³⁵


Based on wound assessment and clinical judgment, NPWT may be appropriate for VLU management. Evidence supports positive effects with the use of NPWT for wound management in general.³ NPWT is utilized across the continuum of care and has substantial amounts of clinical outcomes data demonstrating efficacy in creating an environment that promotes healing in a wide variety of wounds³⁶ whereas V.A.C.[®] Therapy remains the most published of all commercial systems³⁷.

3M offers a portfolio of proven NPWT options that are indicated for the management of venous insufficiency ulcers. The ActiV.A.C.™ Therapy System is a portable NPWT device for the mobile patient with SensaT.R.A.C.™ Technology and Seal Check™ Feature to help maintain pressure at the wound site and detect leaks. The Snap™ Therapy System is a mechanically powered disposable NPWT system that's discreet, silent and lightweight – allowing patients to sleep with minimal interference and shower with the unit in place. The SNAP™ Therapy System is particularly appropriate for ambulatory patients with lower extremity, shallow, small to medium DFUs and VLUs.³8,³9



Therapy System

Therapy System



3M solutions for VLU management

Your patients count on you to help reduce the pain and discomfort caused by VLUs. It's possible when you employ best practices in compression therapy, skin and wound care to aid in their healing process.

Provide therapeutic compression

3M[™] Coban[™] 2 Two-Layer Compression System



3M[™] Coban[™] 2 Lite Two-Layer Compression System



Protect skin

Routine skin protection

3M[™] Cavilon[™] No Sting Barrier Film



At-risk or damaged skin protection



Prepare wound bed

Manage biofilm/bioburden

3M™ Kerracontact™ Ag Dressing

A silver wound contact dressing comprising three layers: two non-adherent polyethylene mesh, and a polyester core. All three layers are coated with Ag Oxysalts™.



Provide collagen

3M[™] Promogran Prisma[™] Wound Balancing Matrix



Optimize wound environment

Manage exudate

3M™ Kerramax Care™ Super-Absorbent Dressing



3M[™] Tegaderm[™] Silicone Foam Dressings



3M[™] Tegaderm[™] High Performance Foam Dressings



3M[™] Snap[™] Therapy



3M[™] ActiV.A.C.[™] Therapy

Supports granulation



References

- Leg ulcer venous NICE Guidance Last revised in January 2021.

 O'Meara S, Cullum N, Nelson EA, & Dumville, JC. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews. 2012; (11).
- O'Donnell TF, Passman MA, Marston EA, et. al. Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum. Journal of Vascular Surgery. 2014; 60(2), 3S-59S.

 Wound, Ostomy, and Continence Nurses Society. (2019). Guideline for management of wounds in patients with lower-extremity venous disease. Mt. Laurel, NJ: Author. 3.
- 5. Guest JF, Ayoub N, McIlwraith T et al (2016) Health economic burden that different wound types impose on the UK's National Health Service. Int Wound J 14(2): 322-30.
- Leg ulcer venous - NICE Guidance - Last revised in January 2021.
- Weller C, Buchbinder R, Johnston R. Interventions for helping people adhere to compression treatments for venous leg ulceration (Review). Cochrane Database Syst Rev. 2013:9.
- Mosti G, Partsch H. Measuring venous pumping function by strain-gauge plethysmography. International Angiology. 2010; 29 (5):421-425
- 10.
- Partsch H. The Static Stiffness Index: A Simple Method to Assess the Elastic Property of Compression Material In Vivo. Dermatol Surg. 2005; 31:625–630.

 Partsch H, and Mortimer P. Compression for leg wounds. British Journal of Dermatology. 2015 (173): 359-369.

 Partsch H, Moffatt C. An overview of the science behind compression bandaging for lymphoedema and chronic oedema. Compression Therapy: A Position Document on Compression Bandaging. International Lymphoedema Framework in Association with the World Alliance for Wound and Lymphoedema Caré. 2012; 12-22
- Moffatt C, Partsch H, Schuren J, et al. Compression Therapy. A position document on compression bandaging. The International Lymphoedema Framework. 2012. Mosti G. Venous ulcer treatment requires inelastic compression. Phlebologie 2018. 47(01): 7-12. 12.
- 13.
- Mosti G, Crespi A, Mattaliano V. Comparison Between a New, Two-component Compression System with Zinc Paste Bandages for Leg Ulcers Healing: A Prospective, Multicenter, Randomized, Controlled Trial Monitoring Sub-bandage Pressures. Wounds. 2011;23(5):126–134.

 Moffatt C, Edwards L, Collier M, et al. A randomized controlled 8-week crossover clinical evaluation of the 3M™ Coban™ 2 Layer Compression System versus
- 15. Profore™ to evaluate product performance in patients with venous leg ulcers. Int Wound J. 2008;5(2);267–279.
- Tucker J, Peterson L, Rauch D, Walters SA. Pressure and slippage during 48 hours of compression therapy: a study on healthy volunteers. Poster presented at SAWC; 16. April 25, 2018; Charlotte, USA.
- Schnobrich E, Solfest S, Bernatchez S, Zehrer C, Tucker J, Walters SA. 7-Day, In-use Assessment of a Unique, Innovative Compression System. Data on file at 3M. Poster presented at SAWC; April 30, 2006; San Antonio, USA.

 Guest JF, Gerrish A, Ayoub N, Vowden K, Vowden P. Clinical outcomes and cost-effectiveness of three alternative compression management systems used in the
- 18.
- management of venous leg ulcers. Journal of Wound Care. 2015;24(7):300–310.

 Guest JF, Fuller GW, Vowden P. Clinical outcomes and cost-effectiveness of three different compression systems in newly diagnosed venous leg ulcers in the UK. Journal of Wound Care. 2017;26(5):244–254. 19.
- 20. Bryant R. Types of Skin Damage and Differential Diagnosis. In: Bryant BA, Nix DP. In: Acute & Chronic Wounds; Current Management Concepts, 5th ED. St. Louis, MO: Elsevier Mosby; 2016:82-108.
 Brennan MR, Milne CT, Agrell-Kann M, Ekholm BP. Clinical Evaluation of a Skin Protectant for the Management of Incontinence Associated Dermatitis: An Open-Label,
- Non-randomized, Prospective Study. J of Wound, Ostomy & Continence Nursing. 2017;44(2):172-180.

 22. Bernatchez S, Mathisen M, Grove G, Houser T. Durability of an Advanced Skin Protectant Compared with Other Commercially Available Products in Healthy Human Volunteers. Wounds. 2018; 30(9):269–274.
- Malone M, Bjarnsholt T, McBain AJ, et al. The prevalence of biofilms in chronic wounds: A systematic review and meta-analysis of published data. J. Wound Care.
- 2017; 26, 20–25.
 World Union of Wound Healing Societies (WUWHS), Florence Congress, Position Document. Management of Biofilm. Wounds International 2016.
- Wardle D. CHC-R629 Summary of Kerracontact Ag Shelf Life Studies. Crawford Healthcare Ltd. CHC-R629. Knutsford, UK: 2018
- Lanzara S, Zamboni P. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. Poster presented at European Wound Management Association (EWMA); May 14-16, 2008; Lisbon, PT.
- Cotton S. The management of a chronic leg ulcer using KERRAMAX CARE™ Super-Absorbent Dressing under compression. Poster presented at Wounds UK;
- November 2015; Harrogate, UK.
 28. Rose R. A large clinical evaluation assessing the tolerance & effectiveness of super-absorbent dressing, KERRAMAX CARE™. Poster presented at Wounds UK; November 2015; Harrogate, UK.
- 29. Cooper R. An investigation into the ability of KERRAMAX CARE™ and KERRAFOAM™ to bind bacteria. Cardiff Metropolitan University. September 2013. 30. Thomas H, Westgate SJ. An in vitro comparison of MRSA and P. aeruginosa sequestration by five super-absorbent wound dressings. Poster presented at EWMA; 11- 13 May 2016; Bremen, Germany.
- 31. 3M. Determination of free swell absorption and fluid retention, and absorption capacity under pressure of KerraMax Care. Internal report CHCR596. 2017.
 32. Hughes M. A large-scale evaluation of managing moderate and highly exuding wounds in the community. Wounds UK. 2017;13(3):78-85.
 33. Morykwas MJ, Simpson J, Punger K, Argenta A, Kremers L, Argenta J. Vacuum-assisted closure: state of basic research and physiologic foundation. Plastic
- Reconstructive Surgery. 2006; 117:1215-126S.

 34. 3M data on file. LAB-05-385368. Median wear times. 4×4 and 6×6 dressings, based on *in vivo* studies EM-13977 and EM-13978.
- Orgill DP, Bayer LR. Negative pressure wound therapy: past, present and future. International Wound Journal. 2013; 10:15-19.
- 36. KCI. Cumulative NPWT Wounds. 2018 37. KCI. Percentage of V.A.C. Therapy Articles vs. Comp Articles. May 7, 2020.
- 38. Armstrong DG, Marston WA, Reyzelman AM, Kirsner RS. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy
- devices: a multicenter randomized controlled trial. Wound Rep Reg 2012; 20(3):332-341.

 39. Marston WA, Armstrong DG, Reyzelman AM, Kirsner RS. A Multicenter Randomized Controlled Trial Comparing Treatment of Venous Leg Ulcers Using Mechanically Versus Electrically Powered Negative Pressure Wound Therapy. Advances in Wound Care. 2015;4(2):75-82. doi:10.1089/wound. 2014.0575.

